ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Dermata Therapeutics Inc

Dermata Therapeutics Inc (DRMA)

0.7123
-0.0217
(-2.96%)
0.7235
0.0112
(1.57%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.7235
Bid
0.705
Ask
0.7235
Volume
33,711
0.70 Day's Range 0.732
0.6611 52 Week Range 5.00
Market Cap
Previous Close
0.734
Open
0.7198
Last Trade Time
Financial Volume
$ 24,234
VWAP
0.718867
Average Volume (3m)
1,548,287
Shares Outstanding
6,378,118
Dividend Yield
-
PE Ratio
-0.37
Earnings Per Share (EPS)
-1.93
Revenue
-
Net Profit
-12.29M

About Dermata Therapeutics Inc

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its p... Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Dermata Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DRMA. The last closing price for Dermata Therapeutics was $0.73. Over the last year, Dermata Therapeutics shares have traded in a share price range of $ 0.6611 to $ 5.00.

Dermata Therapeutics currently has 6,378,118 shares outstanding. The market capitalization of Dermata Therapeutics is $4.68 million. Dermata Therapeutics has a price to earnings ratio (PE ratio) of -0.37.

DRMA Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.03154.552023121390.6920.80.692928650.75312725CS
4-0.0984-11.9722593990.82190.850.6611751910.74076569CS
12-0.4503-38.36258306361.17382.370.661115482871.34553805CS
26-0.4065-35.97345132741.132.370.66119195591.31858267CS
52-2.2765-75.8833333333350.661111537772.0774885CS
156-137.5165-99.476634838138.24249.60.661199464043.7208933CS
260-1391.2765-99.9480244253139216680.6611855299102.59828274CS

DRMA - Frequently Asked Questions (FAQ)

What is the current Dermata Therapeutics share price?
The current share price of Dermata Therapeutics is $ 0.7235
How many Dermata Therapeutics shares are in issue?
Dermata Therapeutics has 6,378,118 shares in issue
What is the market cap of Dermata Therapeutics?
The market capitalisation of Dermata Therapeutics is USD 4.68M
What is the 1 year trading range for Dermata Therapeutics share price?
Dermata Therapeutics has traded in the range of $ 0.6611 to $ 5.00 during the past year
What is the PE ratio of Dermata Therapeutics?
The price to earnings ratio of Dermata Therapeutics is -0.37
What is the reporting currency for Dermata Therapeutics?
Dermata Therapeutics reports financial results in USD
What is the latest annual profit for Dermata Therapeutics?
The latest annual profit of Dermata Therapeutics is USD -12.29M
What is the registered address of Dermata Therapeutics?
The registered address for Dermata Therapeutics is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Dermata Therapeutics website address?
The website address for Dermata Therapeutics is www.dermatarx.com
Which industry sector does Dermata Therapeutics operate in?
Dermata Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RBNERobin Energy Ltd
$ 13.85
(313.43%)
101.81M
OPOceanPal Inc
$ 1.63
(125.45%)
80.28M
LGHLWLion Group Holding Ltd
$ 0.0052
(116.67%)
6.87M
NEONNeonode Inc
$ 16.83
(68.47%)
4.78M
ICONIcon Energy Corporation
$ 2.90
(62.01%)
59.04M
SBETSharpLink Gaming Inc
$ 9.2275
(-71.63%)
41.92M
AIHSSenmiao Technology Ltd
$ 0.381
(-63.01%)
16.8M
CHSNChanson International Holding
$ 0.22
(-60.00%)
15.15M
KWMK Wave Media Ltd
$ 2.91
(-50.43%)
2.59M
JZXNJiuzi Holdings Inc
$ 1.56
(-46.39%)
2.24M
HCTIHealthcare Triangle Inc
$ 0.0201
(-33.00%)
856.89M
GNLNGreenlane Holdings Inc
$ 0.0101
(-34.42%)
792.34M
CGBSCrown LNG Holdings Ltd
$ 0.1104
(31.43%)
788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.655
(3.81%)
246.13M
NVDANVIDIA Corporation
$ 141.97
(-2.09%)
180.81M

DRMA Discussion

View Posts
Monksdream Monksdream 2 months ago
DRMA, new 52 week low
👍️0
glenn1919 glenn1919 2 months ago
drma.....................................................................P/M
👍️0
subslover subslover 2 months ago
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -

- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -

- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne -

SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints as early as week 4, which occurred after just four treatments with XYNGARI™.

XYNGARI™ Phase 3 STAR-1 Topline Week 4 Efficacy Results

In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured timepoint) when compared to placebo.

Investigator Global Assessment: Patients achieving a 2-point reduction AND score of 0 or 1 ("clear" or "almost clear")


Week 4

XYNGARI™ (n=342)

11.9%

Placebo (n=178)

6.2%

p-value

p < 0.05

Mean change from baseline in inflammatory lesion count


Week 4

XYNGARI™ (n=342)

-11.4

Placebo (n=178)

-8.6

p-value

p < 0.001

Mean change from baseline in non-inflammatory lesion count


Week 4

XYNGARI™ (n=342)

-12.4

Placebo (n=178)

-8.8

p-value

p < 0.001

"We are very excited to see such great separation from placebo as early as week 4, after just four once-weekly treatments, which we believe shows how quickly XYNGARI™ can work for some patients," commented Christopher Nardo, Ph.D., Chief Development Officer of Dermata. "We believe acne patients are looking for a product that can reduce their inflammatory lesions as quickly as possible, which reduces the appearance of acne, and we think XYNGARI's™ early efficacy could be a strong driver of patient compliance. We expect these data, coupled with the fact that XYNGARI™ only needs to be applied once per week, will help differentiate XYNGARI™ from other products currently on the market," concluded Dr. Nardo.

XYNGARI™ Phase 3 STAR-1 Clinical Study Design

The XYNGARI™ Phase 3 STAR-1 clinical study evaluated the efficacy, safety, and tolerability of XYNGARI™ in patients with moderate-to-severe facial acne. The STAR-1 study was a randomized (2:1), double-blind, and placebo-controlled 12 week study which enrolled 520 patients with moderate-to-severe acne, ages 9 years and older in the United States and Latin America. The primary endpoints include the mean change from baseline in inflammatory and noninflammatory lesion counts and the Investigator Global Assessment (IGA) treatment response. IGA is measured on a 5-point scale (0-4), with a treatment response defined as at least a 2-point improvement from baseline and an IGA score of 0 (clear) or 1 (almost clear). Patients were treated once-a-week for 12 weeks with either XYNGARI™ or placebo and were evaluated monthly. The STAR-1 study is the first of two pivotal Phase 3 studies, with the second Phase 3 study to be followed by an extension study. If positive, the results of the Phase 3 program would be used to support the filing of a new drug application with the U.S. Food and Drug Administration.

About XYNGARI™ (formerly DMT310)

XYNGARI™ is a novel, once-weekly, topical product candidate derived from a freshwater sponge being developed for the treatment of multiple skin diseases. XYNGARI™ has multiple mechanisms of action that includemechanical components and chemical compounds to help treat inflammatory skin diseases, like acne. After processing,
👍️0
madras50 madras50 3 months ago
they could probably make a lot more if they let it run. With the float it has it could fly.
👍️0
PennyPusher786 PennyPusher786 3 months ago
Look at the 6 month and 1 year chart... someone(s) flipping 
👍️0
Werbe Werbe 3 months ago
It doubled this morning, profit takers been loading this most of the month.  This will be a mega company in 3 to 5 years, this acne product is 1 of a kind.
👍️0
madras50 madras50 3 months ago
why is this not moving on phase 3 news?
👍️0
Werbe Werbe 3 months ago
Nice move, this medicine is going to do a lot of good.  Still has a lot of headroom to push imo 
👍️0
glenn1919 glenn1919 3 months ago
DRMA..................................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 3 months ago
DRMA...$2.08...🥳... https://www.prnewswire.com/news-releases/breaking-dermatas-xyngari-phase-3-trial-topline-data-meets-all-primary-endpoints-302412922.html
👍️0
shurtha2000 shurtha2000 3 months ago
On watch
👍️0
Werbe Werbe 3 months ago
Got a bid here @ 1.13s, topline data coming eom. Tight float here and already low market cap, could explode if positive info is released.
👍️0
shurtha2000 shurtha2000 3 months ago
this is a powder keg Triple or Bust
👍️0
Monksdream Monksdream 4 months ago
DRMA reports 2/21
👍️0
georgie18 georgie18 4 months ago
We shall see...🥳
👍️0
HoldEm777 HoldEm777 4 months ago
Seems close… just get that vibe 🤷🏻‍♂️
👍️0
BooDog BooDog 5 months ago
Caught my radar this morning. $1.24 Diluting low floater. I don't want something I need to babysit but watching for a volume/momentum spike. At the market offering, I'm thinking this gets a lot closer to the $. Not sure what the spike in pps was about a few days ago. Looks like a pump & dump for their offering.

My daily...

DRMA
👍️0
glenn1919 glenn1919 5 months ago
DRMA......................................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 months ago
DRMA..............................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 6 months ago
DRMA...$1.44...🥳... https://schrts.co/iCqYCWPv ...Symmetrical Triangle Breakout setting up here...Downtrend Broken...Break/Hold $1.64 and she will run with 2 Million Float...Hit $1.86 in the A/H on Friday...
👍️0
tw0122 tw0122 6 months ago
DRMA THAR and ENTO and holistic MRM
👍️0
subslover subslover 6 months ago
Nice after-hours move up 46%😍
👍️0
glenn1919 glenn1919 6 months ago
DRMA............................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 months ago
DRMA.....................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 8 months ago
DRMA anew 52=week low
👍️0
glenn1919 glenn1919 9 months ago
DRMA.............................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783
👍️0
subslover subslover 9 months ago
$DRMA = We been moving on up!
👍️0
Monksdream Monksdream 9 months ago
DRMA under $2
👍️0
$oldier Hard $oldier Hard 10 months ago
$DRMA, correction, massive volume.
👍️0
$oldier Hard $oldier Hard 10 months ago
$DRMA, great volume again today.
👍️0
dennisv dennisv 10 months ago
Good things are happen!
👍️0
$oldier Hard $oldier Hard 10 months ago
$DRMA heavy volume.
👍️0
glenn1919 glenn1919 10 months ago
DRMA.......................................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 10 months ago
Not you again
👍️0
PonkenPlonken PonkenPlonken 11 months ago
silly mover
👍️0
TIM231 TIM231 11 months ago
DRMA just halted to upside
👍️0
Awl416 Awl416 11 months ago
These bots are ruthless
👍️0
glenn1919 glenn1919 11 months ago
DRMA..........................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 11 months ago
Cha ching
👍️0
Awl416 Awl416 11 months ago
Too funny
👍️0
Monksdream Monksdream 11 months ago
Whoops, I did it, again
👍️0
Awl416 Awl416 11 months ago
Get your life jacket on
👍️0
Awl416 Awl416 11 months ago
Hahahahahah
👍️0
subslover subslover 11 months ago
I must be dreaming!
👍️0
Awl416 Awl416 11 months ago
LOL
👍️0
Awl416 Awl416 11 months ago
New lows
👍️0
Monksdream Monksdream 11 months ago
DRMA new 52 week low
👍️0
Monksdream Monksdream 11 months ago
DRMA under $2
👍️0
Awl416 Awl416 11 months ago
Yawn…
👍️0
$oldier Hard $oldier Hard 11 months ago
$DRMA 562,000 O/S and traded over a mil today..
👍️0

Your Recent History

Delayed Upgrade Clock